NeuroAD Therapy System: Clinical trial data

The double-blind, U.S. and Israeli trial in 131 patients with mild to moderate AD showed that NeuroAD did not significantly improve ADAS-Cog score from baseline to week 12 vs. placebo. In the subgroup of patients with mild disease, NeuroAD significantly improved ADAS-Cog by 1.8 points.

NeuroAD non-significantly improved CGI-C from baseline to week 12 vs. placebo by 0.4 points. In patients with mild disease, NeuroAD improved CGI-C by 0.45 points. In the NeuroAD-treated arm, 16% of patients experienced deterioration as measured by CGI-C compared to 42% of patients receiving placebo. ...